Latest & greatest articles for fluoxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluoxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluoxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluoxetine

21. Light therapy and fluoxetine similarly effective for improving seasonal affective disorder

Light therapy and fluoxetine similarly effective for improving seasonal affective disorder Light therapy and fluoxetine similarly effective for improving seasonal affective disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Light therapy and fluoxetine similarly effective for improving seasonal affective disorder Article Text Therapeutics Light therapy and fluoxetine similarly effective for improving seasonal affective disorder Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse

Evidence-Based Mental Health2008

22. Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine

Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine Article Text Therapeutics Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine Statistics from

Evidence-Based Mental Health2008

23. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation

The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation Kongsakon R, Bunchapattanasakda C Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of escitalopram versus fluoxetine and venlafaxine for the treatment of major depressive disorder. The authors concluded that escitalopram was more

NHS Economic Evaluation Database.2008

24. Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression

Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression Article Text Therapeutics Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone

Evidence-Based Mental Health2007

25. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study.

Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. OBJECTIVE: To compare the risk of suicide in adults using the antidepressant venlafaxine compared with citalopram, fluoxetine, and dothiepin. DESIGN: Retrospective cohort study. SETTING: UK General Practice Research Database. PARTICIPANTS: 219,088 patients, aged 18-89 years, who were prescribed venlafaxine, citalopram, fluoxetine, or dothiepin from 1995 to 2005. MAIN OUTCOME (...) MEASURES: Completed suicide and attempted suicide. RESULTS: Venlafaxine users had a higher burden of risk factors for suicide, including previous suicide attempts and proxies for severe depression or depression that was difficult to treat. In the analysis for completed suicides, unadjusted and adjusted hazard ratios for venlafaxine compared with citalopram were 2.44 (95% confidence interval 1.12 to 5.31) and 1.70 (0.76 to 3.80), for venlafaxine compared with fluoxetine were 2.85 (1.37 to 5.94) and 1.63

BMJ2007 Full Text: Link to full Text with Trip Pro

26. Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment

Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post-treatment Article Text Therapeutics Eye movement desensitisation and reprocessing reduces PTSD symptoms compared with fluoxetine at six months post

Evidence-Based Mental Health2007

27. Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder

Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder Article Text Therapeutics Continuing fluoxetine treatment may delay relapse in children and adolescents with major depressive disorder Free Dr Paul Wilkinson , MB BChir

Evidence-Based Mental Health2006

28. Fluoxetine improves minor depressive disorders

Fluoxetine improves minor depressive disorders Fluoxetine improves minor depressive disorders | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine improves minor depressive disorders Article Text Therapeutics Fluoxetine improves minor depressive disorders Free Philip J Cowen , MD, FRCPsych Statistics from Altmetric.com No Altmetric data available for this article. Judd LL, Rapaport MH, Yonkers KA, et al . Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry 2004 ; 161 : 1864

Evidence-Based Mental Health2006

29. Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder

Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder Article Text Treatment Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major

Evidence-Based Nursing (Requires free registration)2006

30. Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder

Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder Article Text Therapeutics Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder Free Bernadka Dubicka , MD , Paul

Evidence-Based Medicine (Requires free registration)2006

31. Fluoxetine plus cognitive behavioural therapy improves symptoms of major depressive disorder in adolescents

Fluoxetine plus cognitive behavioural therapy improves symptoms of major depressive disorder in adolescents Fluoxetine plus cognitive behavioural therapy improves symptoms of major depressive disorder in adolescents | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine plus cognitive behavioural therapy improves symptoms of major depressive disorder in adolescents Article Text Therapeutics Fluoxetine plus cognitive behavioural therapy improves symptoms of major depressive disorder in adolescents Free Andrew C Leon , PhD Statistics from

Evidence-Based Mental Health2006

32. Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes

Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Article Text Therapeutics Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Free Christopher D Byrne , FRCP, FRCPath, PhD , Sarah Wild , MRCP, MRCGP, MFPHM, PhD Statistics from Altmetric.com No Altmetric

Evidence-Based Medicine (Requires free registration)2006

33. Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine

Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine Serrano-Blanco A, Gabarron E, Garcia (...) for persons suffering from depressive disorders. Fluoxetine (FLU), a selective serotonin reuptake inhibitor, was compared with imipramine (IMI), a tricyclic antidepressant. The mean starting dosage was 19.4 mg for FLU and 33.5 mg for IMI. The mean daily dosage at day 30 was 20.7 mg for FLU and 58.3 mg for IMI. Type of intervention Treatment and rehabilitation. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged 18 to 65 years who were diagnosed

NHS Economic Evaluation Database.2006

34. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial.

Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. 16772623 2006 06 14 2006 06 19 2016 10 17 1538-3598 295 22 2006 Jun 14 JAMA JAMA Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. 2605-12 Antidepressant medication is frequently prescribed for patients with anorexia nervosa. To determine whether fluoxetine can promote recovery and prolong time-to-relapse among patients with anorexia nervosa following weight restoration (...) to receive fluoxetine or placebo and were treated for up to 1 year as outpatients in double-blind fashion. All patients also received individual cognitive behavioral therapy. The primary outcome measures were time-to-relapse and the proportion of patients successfully completing 1 year of treatment. Forty-nine patients were assigned to fluoxetine and 44 to placebo. Similar percentages of patients assigned to fluoxetine and to placebo maintained a body mass index of at least 18.5 and remained in the study

JAMA2006

35. Cognitive therapy is more effective than fluoxetine in people with generalised social phobia

Cognitive therapy is more effective than fluoxetine in people with generalised social phobia Cognitive therapy is more effective than fluoxetine in people with generalised social phobia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cognitive therapy is more effective than fluoxetine in people with generalised social phobia Article Text Therapeutics Cognitive therapy is more effective than fluoxetine in people with generalised social phobia Free Steven Taylor , PhD Statistics from Altmetric.com No Altmetric data available for this article. Clark DM

Evidence-Based Mental Health2005

36. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. 15315995 2004 08 18 2004 08 23 2016 10 17 1538-3598 292 7 2004 Aug 18 JAMA JAMA Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. 807-20 Initial treatment of major depressive disorder (...) . The trial was conducted at 13 US academic and community clinics between spring 2000 and summer 2003. Twelve weeks of (1) fluoxetine alone (10 to 40 mg/d), (2) CBT alone, (3) CBT with fluoxetine (10 to 40 mg/d), or (4) placebo (equivalent to 10 to 40 mg/d). Placebo and fluoxetine alone were administered double-blind; CBT alone and CBT with fluoxetine were administered unblinded. Children's Depression Rating Scale-Revised total score and, for responder analysis, a (dichotomized) Clinical Global

JAMA2004

37. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.

Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. 11743835 2001 12 17 2002 01 14 2016 10 17 0098-7484 286 23 2001 Dec 19 JAMA JAMA Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. 2947-55 Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressant, yet it is not known whether one SSRI is more effective than another. To compare the effectiveness of 3 (...) SSRIs (paroxetine, fluoxetine, and sertraline) in depressed primary care patients. Open-label, randomized, intention-to-treat trial, with patient enrollment occurring in April-November 1999. Thirty-seven clinics in 2 US primary care research networks. A total of 573 depressed adult patients for whom their primary care physician thought that antidepressant therapy was warranted and who completed a baseline interview. Patients were randomly assigned to receive paroxetine (n = 189), fluoxetine (n = 193

JAMA2001

38. Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France

Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Brown M C, van Loon J M, Guest J F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The new antidepressant drug mirtazapine was compared with fluoxetine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with moderate (17-Hamilton-Depression, HAM-D, score of 20 to 25) or severe

NHS Economic Evaluation Database.2000

39. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK

Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK Borghi J, Guest J F Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients in the UK

NHS Economic Evaluation Database.2000

40. Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial

Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial Sacristan J A, Gilaberte I, Boto B, Buesching D P, Obenchain (...) R L, Demitrack M, Sola V P, Alvarez E, Artigas F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Fluoxetine plus pindolol for patients with depressive disorder. Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.2000